StratDeck

Two stocks in Healthcare

argenx vs Bayer Aktiengesellschaft: profit, growth, debt and price compared

argenx is stronger on 3 of 6 figures: profit margin, sales growth and debt. Bayer Aktiengesellschaft is stronger on 2: price for its expected profit and price trend.

Figures as of 18 November 2026Yahoo Finance
Explore argenx's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

argenx and Bayer Aktiengesellschaft side by side
argenxARGX.BRBayer AktiengesellschaftBAYN.DE
Net marginStronger: 31.7%−3.2%
Revenue growth, past yearStronger: +52.10%+4.10%
Debt to equityStronger: 0.6%134.4%
Forward P/E26.9×Stronger: 11.5×
Dividend yield—0.19%
AnalystsBuy · 23Buy · 18
From its 200-day average+11.9%Stronger: +26.0%

Share price over the past year

  • argenx+9.4%
  • Bayer Aktiengesellschaft+82.8%

24 Nov 202518 Nov 2026

argenx or Bayer Aktiengesellschaft: which is stronger?

  • ARGX.BR

    Which is more profitable?

    argenx keeps more of each sale as profit: 31.7% against −3.2%.

  • ARGX.BR

    Which is growing its sales faster?

    argenx is growing its sales faster: +52.10% over the past year, against +4.10%.

  • ARGX.BR

    Which has borrowed less?

    argenx has borrowed less: its debt is 0.6% of what its shareholders own, against 134.4% for Bayer Aktiengesellschaft.

  • BAYN.DE

    Which costs less for the profit it is expected to make?

    Bayer Aktiengesellschaft costs less for the profit it is expected to make: 11.5× its forward earnings, against 26.9×.

  • Which pays more in dividends?

    Bayer Aktiengesellschaft pays 0.19% a year in dividends for what a share costs, where argenx pays none.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • BAYN.DE

    Which is in the stronger price trend?

    Bayer Aktiengesellschaft's price is in the stronger trend: 26.0% above its 200-day average, against 11.9% above.

What each company does

ARGX.BRargenx

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

Reports results on 25 February 2027

BAYN.DEBayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.

Reports results on 24 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.